

Special Issue

Vaccines Targeting Dendritic Cells

Message from the Guest Editors

Dendritic cells (DCs) act as the sentinels of the immune system and initiate and orchestrate immune responses. Current DC-based immunotherapy approaches have shown promise in cancer treatment and prevention. These approaches involve the activation of DCs following the in vitro and in vivo delivery of antigens directly to them using specialized systems such as nanoparticles or viral vectors. These strategies aim to induce humoral immunity, prime T helper cells, and/or elicit CTL responses. Broadly, the role of DCs in modulating adaptive immune responses offers new avenues for vaccine development. This Special Issue aims to compile the latest research on the ongoing advancements in vaccines targeting DCs. We welcome the submission of reviews, research articles, and short communications that highlight recent breakthroughs in DC-targeting vaccines, as well as manuscripts addressing the challenges and limitations encountered in this field.

Guest Editors

Dr. Ronald A. Backer

Luminex Corporation – A DiaSorin Company, Austin, TX 78727, USA

Prof. Dr. Björn E. Clausen

Institute for Molecular Medicine, Paul Klein Center for Immune Intervention, University Medical Center of the Johannes Gutenberg-University Mainz, Langenbeckstrasse 1, 55131 Mainz, Germany

Deadline for manuscript submissions

closed (31 October 2025)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/203634

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).